Recurrence of morphea after successful ultraviolet A1 phototherapy: A cohort study - 14/02/14
Abstract |
Background |
Studies support efficacy of ultraviolet (UV)A1 phototherapy, but little is known about recurrence after successful UVA1 treatment.
Objective |
We sought to determine the frequency of recurrent activity after UVA1 phototherapy and variables associated with recurrence.
Methods |
This was a case series and prospective cohort study of patients treated with UVA1 phototherapy with minimum 6 months of follow-up. Demographics, clinical features, and cumulative UVA1 dose were analyzed for association with recurrence.
Results |
Of 37 patients, 46% (n = 17) had recurrence of active morphea lesions after successful UVA1 phototherapy. Two-year and 3-year (after the last UVA1 phototherapy treatment) recurrence rates were 44.5% (95% confidence interval 30.1%-62.2%) and 48.4% (95% confidence interval 33.2%-66.1%), respectively. The only variable associated with recurrence was duration of morphea before UVA1 (P value = .02, hazard ratio 1.15, 95% confidence interval 1.06-1.27).
Limitations |
The sample size limits conclusions.
Conclusion |
With the exception of increased duration of morphea, risk of recurrence is no different in adults and children, or between morphea subtypes, skin types, and medium- to high-dose regimens. This indicates treatment doses in the medium-high UVA1 range are adequate with respect to frequency of recurrence.
Le texte complet de cet article est disponible en PDF.Key words : localized scleroderma, morphea, phototherapy, ultraviolet A1 phototherapy
Abbreviations used : CI, MAC, UV
Plan
Research for this article was supported in part by National Institutes of Health (NIH) grant K23AR056303-4. This work was conducted with support from UT-STAR, NIH/National Center for Advancing Translational Sciences (NCATS) grant UL1TR0000451. The content is solely the responsibility of the authors and does not necessarily represent the official views of UT-STAR, University of Texas Southwestern Medical Center at Dallas and its affiliated academic and health care centers, NCATS, or NIH. |
|
Conflicts of interest: None declared. |
|
Reprints not available from the authors. |
Vol 70 - N° 3
P. 481-488 - mars 2014 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?